Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

50.65 +0.25 (+0.50%)
Official Closing Price Updated: 7:00 PM EDT, May 19, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 19,865,557
Open 50.00
Bid (Size) 50.65 (20)
Ask (Size) 50.73 (1)
Prev. Close 50.40
Today's Range 49.59 - 50.88
52wk Range 38.48 - 61.71
Shares Outstanding 5,606,688,356
Dividend Yield 3.08%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
North Carolina Physicians' Group Calls for Halt to Atrium COVID Vaccine Trial for Children
The North Carolina Physicians for Freedom (NCPFF), a large network of physicians and other health care professionals, called for the cessation of a clinical trial announced by the Atrium hospital... 
Via Newswire.com
Topics Death
Exposures COVID-19 Death
Pfizer, NIH Mulling Study For Longer Paxlovid Course To Combat Reinfections
 
Via Benzinga

Performance

YTD
-10.59%
-10.59%
1 Month
+0.94%
+0.94%
3 Month
+3.58%
+3.58%
6 Month
-1.48%
-1.48%
1 Year
+27.17%
+27.17%

More News

Read More
Read Why Pfizer Is Limiting Supply Of Paxlovid For Combination Studies: Bloomberg
Via Benzinga
Upcoming U.S. FDA Decision A Potentially Major De-Risk Event For Revive Therapeutics
Via Benzinga
Looking At Pfizer's Recent Whale Trades
Via Benzinga
FDA Declines Emergency Use Request For An Antidepressant As COVID-19 Treatment
Via Benzinga
Thoughts For Thursday: Ugly and Uglier
Via Talk Markets
3 Safe Stocks to Buy As We Head For a Recession
Via Talk Markets
The Daily Biotech Pulse: Pfizer/BioNTech's COVID-19 Booster For Kids, Moderna Starts First African Trial Of mRNA HIV Vaccine, Tonix Extends COVID-19 Antiviral Research Pact
Via Benzinga
EXCLUSIVE: Be The House Not The Gambler — How To Use Options To Improve Performance
Via Benzinga
FDA Gives Green Signal To Pfizer/BioNTech's COVID-19 Booster For Kids 5-11 Years
Via Benzinga
Awardees named for $20 million project to foster diversity in clinical trial research
Via NewMediaWire
Pfizer Retakes A Key Line — And Drags BioNTech, Moderna With It
Via Investor's Business Daily
Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
From Pfizer Inc.
Via Business Wire
Pain Management Drugs Market Increased Research Activities Boost Demand Opportunities
Via iCrowdNewswire
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Tuesday, May 17
Via Benzinga
FDA May Authorize Pfizer-BioNTech's COVID-19 Booster For 5-11 Year Kids Soon: NYT
Via Benzinga
Inflation May Have Peaked: What to Do Now
Via InvestorPlace
Contraceptives Market New Innovations Trends, Research, Global Share and Growth Factor
Via iCrowdNewswire
Topics Economy
Exposures COVID-19 Supply Chain
Asia-Pacific Anti-Inflammatory Therapeutics Market Qualitative Insights on Application & Outlook by Share, Future Growth
Via iCrowdNewswire
Topics Intellectual Property
Exposures Intellectual Property
Insider Buying Remains Elevated For A Second Week $SBUX $UBER $RILY
Via Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Monday, May 16
Via Benzinga
Pfizer/BioNTech COVID-19 Vaccine's European Delivery Takes Backseat To Help Booster Campaign
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.